Methotrexate 10 mg tablets by all Sub-ICB Locations

Why it matters: The BNF states: Note that the dose is a weekly dose.To avoid error with low-dose methotrexate, it is recommended that:

• the patient is carefully advised of the dose and frequency and the reason for taking methotrexate and any other prescribed medicine (e.g.folic acid);
• Prescribe only if no other item or intervention is clinically appropriate.
• Prescribe only if no other item or intervention is available.
• the prescription and the dispensing label clearly show the dose and frequency of methotrexate administration;
• the patient or their carer is warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort, and dark urine), and respiratory effects (e.g. shortness of breath)
.

You can read more in our paper on trends and variation in unsafe prescribing of methotrexate.

Description: Prescribing of methotrexate 10mg tablets as a percentage of prescribing of all methotrexate tablets

Explore:

• View this measure on the analyse page.
• View technical details for this measure.

Tagged as: Standard, Safety (or browse all measures)

Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.

View measure for NHS England combined →

---

Fetching data...